ID Biomedical starts trials for new "superbug" test:
This article was originally published in Clinica
ID Biomedical, of Vancouver, British Columbia, has begun a clinical trial of its rapid gene-based test for detecting a form of the enterococcus bacteria that is resistant to commonly used antibiotics. The Velogene Rapid VRE Identification assay, detects vancomycin resistant enterococcus, which is often acquired in hospitals. Based on the company's proprietary Cycling Probe Technology, the test detects the vanA and vanB genes, which are responsible for drug resistance. The company already has US marketing clearance for its methicillin-resistant Staphylococcus aureas test.